![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Shionogi to co-promote Noven's Brisdelle alongside Osphena in the US
Executive Summary
Hisamitsu Pharmaceutical Co. Inc.’s Noven Pharmaceuticals Inc. (women’s health and neurology therapeutics) granted Shionogi Inc. exclusive multi-year US rights to co-promote Brisdelle (paroxetine) 7.5mg capsules. The selective estrogen reuptake modulator is the first and only FDA-approved non-hormonal drug for moderate-to-severe hot flashes accompanying menopause.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice